Zota Health Care Ltd (ZOTA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Zota Health Care Ltd on NSE and BSE, with an AI summary of each filing.
ZOTA: Zota Health Care Limited has informed the Exchange about Transcript of Earnings Conference Call on Financial Results for the quarter ended September 30, 2026
Transcript · 04 Nov 2026, 12:28 am
Zota Health Care Reports Strong Q2FY27 Revenue Growth and EBITDA Turnaround Zota Health Care reported a 54.6% YoY rise in consolidated revenue to ₹199.33 crore for Q2FY27, up 14.8% QoQ, driven by a 76.3% YoY surge in Davaindia sales to ₹168.47 crore (82% of revenue). Consolidated EBITDA turned positive at ₹7.92 crore (3.97% margin) versus negative ₹9.55 crore in Q1FY27, narrowing net loss to ₹25.96 crore. Davaindia's store network reached 2,840 as of 30th Sep'26. Management plans to add 400-450 stores in H2FY27, targeting Davaindia division EBITDA profitability by Q4FY27.
ZOTA: Zota Health Care Limited has informed the Exchange about Audio Recording Link of Earnings Conference Call on financial results for the quarter and half year ended September 30, 2026
Audio / Video · 29 Oct 2026, 11:56 pm
Zota Health Care Discloses Q2 and H1 Earnings Call Audio Recording Link Zota Health Care Limited has informed the National Stock Exchange of India regarding the availability of the audio recording for its earnings conference call held on 29th Oct'26. The call covered the operational and financial performance for the quarter and half-year ended 30th Sep'26, pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The recording has been made accessible to investors and stakeholders on the company's official website.
Zota Health Care LImited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Others (Uncategorized) · 28 Oct 2026, 11:58 pm
Zota Health Care Reports Zero Deviation in QIP Fund Utilization for Sep'26 Quarter Zota Health Care confirmed no deviation or variation in utilizing proceeds from its 17th Dec'25 Qualified Institutional Placement for the quarter ended 30th Sep'26. Against total funds raised of ₹34,999.99 lakhs (net proceeds of ₹34,033.24 lakhs post issue expenses), the company has deployed ₹8,286.60 lakhs toward working capital requirements from an allocated ₹13,537.49 lakhs. Additionally, ₹1,814.91 lakhs has been invested in DHML for new COCO stores (₹12,962.50 lakhs allocated) and ₹1,433.60 lakhs deployed for general corporate purposes (₹7,533.25 lakhs allocated), monitored by CRISIL Ratings.
Zota Health Care LImited has informed the Exchange about Investor Presentation
Investor Presentation · 28 Oct 2026, 11:52 pm
Zota Health Care Reports Strong Q2FY27 Revenue Growth and Turnaround to Positive EBITDA Zota Health Care delivered a 54.58% YoY increase in consolidated revenue from operations to ₹19,933.14 lakhs in Q2FY27, driven by a 76.25% YoY rise in Davaindia sales to ₹16,846.81 lakhs. Consolidated EBITDA turned positive to ₹791.72 lakhs (3.97% margin) from a loss in Q1FY27, though net loss stood at ₹2,596.01 lakhs. Davaindia's network expanded to 2,840 stores (1,859 COCO, 981 FOFO), generating quarterly GMV of ₹18,791 lakhs. Management plans to accelerate store additions in H2FY27 while focusing on cash generation and operational efficiency.
ZOTA: Zota Health Care Limited has informed the Exchange regarding a press release dated October 28, 2026, titled "ZOTA: Zota Health Care Limited has informed the Exchange regarding a press release dated October 28, 2026, titled "Zota Health Care Limited Reports Healthy Q2FY27 Performance, Amid Planned Moderation in Store Expansion."
Press Release · 28 Oct 2026, 11:47 pm
Zota Health Care Reports Strong Q2FY27 Revenue Growth and Sequential EBITDA Turnaround Zota Health Care reported a 54.58% YoY rise in consolidated revenue from operations to ₹19,933.14 lakhs for Q2FY27 ending 30th Sep'26, driven by a 76.25% YoY jump in Davaindia sales to ₹16,846.81 lakhs. EBITDA achieved a sharp sequential turnaround to ₹791.72 lakhs (3.97% margin) from a loss of ₹955.40 lakhs in Q1FY27. Davaindia reached 2,840 stores nationwide, generating quarterly GMV of ₹18,791 lakhs. Additionally, the company converted ₹119.52 crore of DHML debt into equity via preferential share allotment.
ZOTA: Zota Health Care Limited has submitted to the Exchange the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on September 30, 2026
Outcome · 28 Oct 2026, 11:17 pm
Zota Health Care Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 19,933 (+54.6% YoY | +14.8% QoQ) ■ EBITDA: 306 (-51.6% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 1.5 (-337 bps YoY | Loss to Profit QoQ) ■ PAT: -2,558 (-60.4% YoY | +41.3% QoQ) ■ EPS (INR): -7.39 (-47.2% YoY | +41.3% QoQ)
ZOTA: Zota Health Care Limited has informed the Exchange about the Intimation of Schedule of Earnings Conference Call on Q2FY27 Results
Intimation · 29 Oct 2026, 12:00 pm
Zota Health Care Schedules Q2FY27 Earnings Conference Call for October 29 Zota Health Care Limited will announce its financial results for the second quarter and half year ended 30th Sep'26 on 28th Oct'26. Following the announcement, the company will host an earnings conference call on 29th Oct'26 at 12:00 hrs IST. Senior management—including Founder and Whole-time Director Himanshu Zota, Managing Director Moxesh Zota, and Group CEO Dr. Sujit Paul—will represent the company to discuss performance across its pharmaceutical, nutraceutical, export, and Davaindia retail generic pharmacy divisions. Universal dial-in numbers are +91 22 6280 1107 and +91 22 7115 8008.
ZOTA HEALTH CARE LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 28 Oct 2026, 5:30 am
Zota Health Care Board to Consider Half-Yearly Financial Results on 28th Oct'26 Zota Health Care Limited has informed the stock exchange that a meeting of its Board of Directors is scheduled for 28th Oct'26. The board will consider and approve the company's unaudited financial results for the half-year period ended Sep'26, alongside other routine business matters.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 28 Oct 2026, 5:30 am
Zota Health Care Schedules Board Meeting for Q2 Results on 28th Oct'26 Zota Health Care Limited has scheduled a meeting of its Board of Directors on 28th Oct'26 at 2:00 PM. The board will meet primarily to consider and approve the unaudited standalone and consolidated financial results, along with the limited review reports, for the quarter and half-year ended 30th Sep'26.
Significant increase in volume has been observed in Zota Health Care LImited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Zota Health Care LImited has submitted their response.
Others (Uncategorized) · 15 Oct 2026, 10:19 pm
Zota Health Care Clarifies Share Volume Surge Is Purely Market Driven Zota Health Care Limited responded on 15th Oct'26 to an NSE surveillance inquiry regarding a significant increase in trading volume. The company confirmed that it has no undisclosed price-sensitive information or impending announcements required under Regulation 30 of SEBI LODR Regulations, 2015. Management reiterated that all material disclosures have been made within mandated timeframes and that the recent movement in the company's share price and trading volume is purely market driven.
ZOTA: Zota Health Care Limited has informed the Exchange about Clarification regarding Increase in Volume
Others (Uncategorized) · 15 Oct 2026, 4:22 pm
Significant increase in volume has been observed in Zota Health Care LImited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Others (Uncategorized) · 14 Oct 2026, 11:42 pm
Exchange Seeks Clarification from Zota Health Care Amid Unusual Volume Surge The stock exchange has sought clarification from Zota Health Care Limited following a significant surge in trading volumes. The regulatory inquiry aims to ensure adequate disclosure of any price-sensitive information and safeguard investor interests. A formal response from the company regarding the volume movement remains awaited.
Zota Health Care Limited has informed the Exchange about Davaindia Stores Update for Q2FY27
Others (Uncategorized) · 02 Oct 2026, 12:08 am
Zota Health Care Reports Q2FY27 Davaindia Store Network Expansion Zota Health Care reported a total operative Davaindia store count of 2,840 as of 30th Sep'26, up from 2,825 as of 30th Jun'26. During Q2FY27, the company opened 20 stores and closed 5, resulting in 15 net additions across 4 COCO stores (reaching 1,859) and 11 FOFO stores (reaching 981). Management noted the slower expansion pace during the quarter was part of a pre-determined strategy, with rapid store expansion scheduled to resume from Q3FY27 onwards.
ZOTA: Zota Health Care Limited has informed the Exchange about Acquisition of 39,228 equity shares of M/s Davaindia Health Mart Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue.
Others (Uncategorized) · 01 Oct 2026, 6:02 pm
Zota Health Care Invests ₹19.91 Crore in Subsidiary Davaindia Health Mart Zota Health Care acquired 39,228 equity shares of its wholly owned subsidiary, Davaindia Health Mart Limited, via a rights issue on 1st Oct'26 for ₹19.91 crore (₹5,075 per share, including a ₹5,065 premium). The cash investment aims to fund working capital and support strategic growth. Davaindia operates 1,855 COCO retail generic pharmacy stores across 23 states and 5 Union Territories as of 30th Jun'26. The subsidiary's turnover grew rapidly to ₹267.71 crore in FY26 from ₹109.93 crore in FY25 and ₹44.77 crore in FY24.
ZOTA: Zota Health Care Limited has informed the Exchange about Acquisition of 21,00,000 equity shares of M/s KMHP Ventures Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue
Others (Uncategorized) · 01 Oct 2026, 5:49 pm
Zota Health Care Subscribes To KMHP Ventures Rights Issue Worth Rs 2.10 Cr Zota Health Care Limited has acquired 21,00,000 equity shares of its wholly owned subsidiary, KMHP Ventures Limited, via a rights issue at Rs 10.00 per share, totaling Rs 2,10,00,000 in cash consideration on 1st Oct'26. KMHP Ventures, incorporated on 13th Jan'26 with Rs Nil turnover in FY 25-26, is rolling out a B2B and B2C generic medicine retail chain under the "Ugo Generic" brand. The strategic investment will fund retail store expansion and meet working capital requirements across a planned Pan-India network.
ZOTA: Zota Health Care Limited has informed the Exchange about Acquisition of 20,20,000 equity shares of M/s Curexis Ventures Private Limited, Wholly Owned Subsidiary of the Company, by way of subscription to the right issue.
Others (Uncategorized) · 01 Oct 2026, 5:43 pm
Zota Health Care Invests ₹4.04 Crore in Subsidiary Curexis Ventures Rights Issue Zota Health Care acquired 2,020,000 equity shares of its wholly owned subsidiary, Curexis Ventures Private Limited, via a rights issue on 1st Oct'26 for ₹4.04 crore (₹20 per share, including a ₹10 premium). Curexis, incorporated on 25th Feb'25 and operator of retail pharmacy brand "SKIA", reported a turnover of ₹1.18 lakh in FY26. Issue proceeds will be utilized to repay unsecured loans availed from Zota Health Care, reducing consolidated group debt and improving overall net worth while maintaining Curexis as a wholly owned subsidiary.
ZOTA: Zota Health Care Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 28, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 30 Sept 2026, 4:45 pm
ZOTA: Zota Health Care Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 28, 2026.
Annual General Meeting · 28 Sept 2026, 6:46 pm
Zota Health Care Limited has informed the Exchange about Communication to Shareholders - Intimation w.r.t Tax Deduction on Dividend.
Dividend · 24 Sept 2026, 11:57 pm
Zota Health Care Outlines TDS Framework for Recommended Final Dividend Zota Health Care has issued tax deduction guidelines for its recommended FY26 final dividend of 10% (Re 1 per share of face value Rs 10). Applicable to shareholders registered as of 21st Sep'26, dividend payments will commence on or after 30th Sep'26 subject to AGM approval. Resident individual shareholders face 10% TDS with a valid PAN, while amounts up to INR 10,000 or valid Form 121 submissions incur nil TDS. Missing or invalid PANs trigger a 20% rate. Non-residents face 20% TDS plus cess/surcharge or applicable DTAA rates.
Zota Health Care Limited has informed the Exchange regarding 'Annual General Meeting Notice Response to Proxy Advisory Firm'.
Annual General Meeting · 22 Sept 2026, 12:04 am
Zota Health Care Limited has informed the Exchange regarding Cessation of Mrs Varshabahen Gaurang Mehta as Non- Executive Independent Director of the company w.e.f. September 09, 2026, upon completion of her tenure.
Change in Management · 18 Sept 2026, 11:31 pm
Zota Health Care Announces Cessation of Independent Director Varshabahen Gaurang Mehta Zota Health Care Limited has informed the stock exchange that Mrs. Varshabahen Gaurang Mehta (DIN: 07611561) ceased to be an Independent Director of the company effective 9th Sep'26. The cessation follows the successful completion of her second tenure on the board, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Zota Health Care Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026
Annual General Meeting · 04 Sept 2026, 1:15 am
Zota Health Care LImited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 21-Sep-2026.
Dividend · 04 Sept 2026, 1:11 am
Zota Health Care Fixes Sep'26 Record Date for Final Dividend and AGM Zota Health Care Limited has set 21st Sep'26 as the official record date to determine shareholder eligibility for its final dividend payout and the upcoming 26th Annual General Meeting.
Zota Health Care Limited has informed the Exchange regarding Appointment of Mr Mahaveer Dhariwal as the Additional Director to be designated as the Non- Executive Independent Director of the company w.e.f. September 03, 2026.
Change in Management · 04 Sept 2026, 1:07 am
Zota Health Care Appoints Independent Director and Sets AGM Record Date On 3rd Sep'26, Zota Health Care appointed Mr. Mahaveer Dhariwal as an Additional Independent Director for a five-year term. The board set 21st Sep'26 as the record date for a 10% final dividend (Re. 1/share) and e-voting eligibility. The 26th AGM is scheduled for 28th Sep'26. Key AGM agenda items include re-appointing Moxesh Zota as MD and approving material related-party transactions, including a Rs. 40 crore unsecured loan and Rs. 100 crore in supply arrangements with subsidiary Everyday Herbal Beauty Care Limited.
Zota Health Care Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Outcome · 04 Sept 2026, 1:03 am
Zota Health Care Board Approves FY26 Dividend, Key RPTs, and Leadership Re-appointments Zota Health Care declared a final dividend of Re. 1 per share for FY26, with a 21st Sep'26 record date, ahead of its AGM on 28th Sep'26. The board re-appointed Moxesh Zota as Managing Director for five years and capped aggregate promoter remuneration at Rs 12 crore annually through FY30. Furthermore, the board approved material related-party transactions with subsidiary Everyday Herbal Beauty Care for FY27, comprising a Rs 40 crore unsecured loan and Rs 100 crore for goods transactions to support retail chain expansion.